CD274 and cancer: Based on a string of success along with the remarkable improvement in the therapeutic outcome, the indications of chemotherapy in combination with ICIs were extended to include a wider spectrum of cancer patients, for example, the combination of atezolizumab (anti-PD-L1) and chemotherapy was approved to treat metastatic non-squamous NSCLC (atezolizumab plus nab-paclitaxel and carboplatin), unresectable locally advanced or metastatic TNBC (atezolizumab plus nab-paclitaxel) and extensive-stage small cell lung cancer (atezolizumab plus carboplatin and etoposide) (39–41).